Related Experiment Video
Updated: Aug 6, 2026
08:48
Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
Published on: June 30, 2023
Mitochondrial alterations in Alzheimer's disease
1Department of Neurology, Aristotelian University, Thessaloniki 54006, Greece. sibh844@otenet.gr
Journal of Alzheimer'S Disease : JAD
|July 29, 2006
Summary
Mitochondrial dysfunction and morphological changes are prominent in Alzheimer's disease (AD) neurons, contributing to energy deficits and neuronal damage. These alterations correlate with synaptic defects, suggesting an early role in AD pathogenesis.
Area of Science:
- Neuroscience
- Cell Biology
- Pathology
Background:
- Mitochondrial dysfunction is a key feature in neurodegenerative disorders, particularly Alzheimer's disease (AD).
- Metabolic disturbances, including altered glucose utilization, oxidative stress, and calcium deregulation, are implicated in AD pathogenesis and linked to mitochondrial defects.
- These cellular defects can create a detrimental cycle of dysfunction and damage, ultimately impairing neuronal survival.
Purpose of the Study:
- To investigate the morphological and morphometric characteristics of mitochondria in neurons affected by Alzheimer's disease.
- To explore the relationship between mitochondrial alterations and synaptic pathology in AD.
- To assess the extent and location of mitochondrial abnormalities across various brain regions in AD.
Main Methods:
- Electron microscopy was employed for detailed ultrastructural examination of mitochondria in neurons from multiple brain regions of AD patients and controls.
- Morphometric analysis was conducted to quantify mitochondrial size and number.
- Immunohistochemistry and other ultrastructural techniques were used to assess cytoskeletal pathology, amyloid deposits, and Golgi apparatus integrity.
Main Results:
- Significant morphological changes in mitochondria were observed in AD neurons, including altered cristae, osmiophilic material accumulation, and reduced size.
- Mitochondrial abnormalities were particularly pronounced in neurons exhibiting dendritic spine loss and shortened dendritic arborization.
- Morphometric analysis revealed a significant reduction in mitochondrial number in Alzheimer's disease brains.
- Mitochondrial alterations were observed independently of cytoskeletal pathology and amyloid deposits but were associated with Golgi apparatus fragmentation.
Conclusions:
- Mitochondrial morphological and morphometric abnormalities are a significant feature of Alzheimer's disease.
- These mitochondrial defects are closely associated with synaptic alterations, suggesting an early and integral role in AD progression.
- The findings highlight the critical involvement of mitochondrial health in neuronal function and survival in the context of neurodegeneration.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:37Mitochondria
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...